We work closely with our funder Unitaid to implement our grant agreement to accelerate access to HIV, hepatitis C and tuberculosis medicines in developing countries. With Unitaid, we are also key partners in the Paediatric HIV Treatment Initiative (PHTI)(See Paediatric HIV Treatment Initiative (PHTI) in Consortia).

More information



We collaborate with UNAIDS on patent landscaping and market forecasting as detailed in the current UNAIDS strategy for 2016-2021.



The World Health Organization

In 2017, the MPP and the World Health Organization established the second three-year work plan as part of our official working relationship. The plan includes collaborating on a wide range of issues including:


The Global Fund to Fight AIDS, Tuberculosis and Malaria

We work with the Global Fund to Fight AIDS, Tuberculosis and Malaria and other partners to accelerate greater access to key new products in Global Fund-supported countries as detailed in the Global Fund’s Market Shaping Strategy.


The World Intellectual Property Organization

We collaborate with the World Intellectual Property Organization (WIPO) in several areas, from licensing terms to patent landscaping and patent transparency. In particular, we have benefited significantly from WIPO’s help in collecting patent status information from national and regional patent offices for inclusion in MedsPaL.

We work closely with several governments to understand treatment needs, current barriers to expanding treatment, current prices in the market and procurement options. Our licences have enabled many developing country governments to procure more affordable medicines for their treatment programmes. Governments interested in working with us should contact policy@stage.mpp.acw.website

We also work with patent offices to collect patent information for inclusion in MedsPaL.

We work with many international, regional and national civil society, community-based organisations and patient groups to understand treatment needs and difficulties with access. Our collaborations focus on working to overcome challenges to expanding treatment, to identify priorities, to obtain feedback on our licences, and to support the data collection needed for our licensing work. We regularly organise consultations with civil society organisations at international and regional conferences. Representatives from civil society organisations and community groups also serve on our Governance Board and Expert Advisory Group.

Paediatric HIV Treatment Initiative (PHTI)

We are a key partner in the Paediatric HIV Treatment Initiative (PHTI), which we established in 2014 with Unitaid and the Drugs for Neglected Diseases initiative (DNDi) to provide World Health Organization-priority formulations for children. The Clinton Health Access Initiative joined the project after its launch, and the WHO now serves as a technical partner. Our work with originator companies has helped resolve IP issues relating to six PHTI current projects. Further, working with generic manufacturers, we are currently spearheading the development of the WHO-recommended first-line treatment for children from three-to-ten years of age, ABC/3TC/EFV, as well as a raltegravir paediatric formulation that is suitable for infants and young children.

The Life Prize for TB drug and regimen development

We are a member of the steering committee of The Life Prize, formerly the 3P Project, a new initiative to improve the way research and development on new tuberculosis (TB) regimens is conducted. The project is a collaboration of many TB actors, international organisations and research institutions, working to jump-start drug discovery through innovative strategies to re-energise the TB pipeline. The Life Prize aims to create a new way of rewarding investment in TB drug development through an open research framework that seeks to balance stewardship, quality, accessibility and affordability concerns. Other partners include Critical Path Institute; the International Union against Tuberculosis and Lung Disease (The Union); Médecins Sans Frontières; Stop TB Partnership (STBP); The Medical Research Council of South Africa; TB Alliance and the World Health Organization.

United States Agency for International Development (USAID) OPTIMIZE Consortium

We are a partner in the OPTIMIZE Consortium, led by Wits RHI from South Africa and funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID). OPTIMIZE aims to accelerate access to simpler, safer and more affordable HIV treatment by integrating clinical research, novel formulation technologies to reduce treatment costs, and accelerated product introduction in developing countries. The formulation technologies include innovation by the University of Liverpool – our licensor and collaborator, and also an OPTIMIZE partner. OPTIMIZE also includes International Center for AIDS Care and Treatment Program (ICAP) at Columbia UniversityMylan Laboratories, the St. Stephen’s AIDS Trust (SSAT) and the University of Cape Town. OPTIMIZE collaborates closely with other partners funded by Unitaid.

Our work relies on partnerships with many other parties in the fields of HIV, hepatitis C and tuberculosis. Collaboration with patent holding companies and universities is critical to our success.

We also sign agreements with generic manufacturers and product developers licensed to develop, produce and distribute medicines at lower cost.

Access the full list of patent holders and generic manufacturers working with the MPP

We look forward to developing relationships with all relevant patent holders, eligible generic manufacturers and product developers to increase access to medicines for people living in developing countries.

We recognise and appreciate the pro bono legal services provided by Dechert LLP, Rajeshwari & Associates, Robins, Kaplan, Miller & Ciresi, and Davis Polk & Wardwell

This website uses cookies to ensure you get the best experience on our website. Learn More